Hans Marcus Bosson
Chief Executive Officer at QUIAPEG PHARMACEUTICALS HOLDING AB
Profile
Hans Marcus Bosson is the founder of Resistentia Pharmaceuticals AB, founded in 1998, where he held the title of Chief Executive Officer until 2010.
He was also the founder of QuiaPEG Pharmaceuticals AB, founded in 2012, where he held the title of Chief Executive Officer & Director.
Currently, he is the CEO & Independent Director at Quiapeg Pharmaceuticals Holding AB since 2017.
Previously, he worked as the Chief Executive Officer at Ryda Bruk AB and as a Director at BioArctic AB.
Mr. Bosson has a graduate degree from Stockholm School of Economics and the University of Stockholm.
Hans Marcus Bosson active positions
| Companies | Position | Start |
|---|---|---|
| QUIAPEG PHARMACEUTICALS HOLDING AB | Chief Executive Officer | 2016-12-31 |
Former positions of Hans Marcus Bosson
| Companies | Position | End |
|---|---|---|
Resistentia Pharmaceuticals AB
 Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Founder | 2010-06-23 |
Ryda Bruk AB
 Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The company is based in Heby, Sweden. | Chief Executive Officer | - |
QuiaPEG Pharmaceuticals AB
 QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Founder | - |
| BIOARCTIC AB | Director/Board Member | - |
Training of Hans Marcus Bosson
| Stockholm School of Economics | Graduate Degree |
| University of Stockholm | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BIOARCTIC AB | Health Technology |
| QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
| Private companies | 3 |
|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Ryda Bruk AB
Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The company is based in Heby, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Hans Marcus Bosson